CR10527A - Inibidores del canal de potasio de imidazol kv1.5 - Google Patents

Inibidores del canal de potasio de imidazol kv1.5

Info

Publication number
CR10527A
CR10527A CR10527A CR10527A CR10527A CR 10527 A CR10527 A CR 10527A CR 10527 A CR10527 A CR 10527A CR 10527 A CR10527 A CR 10527A CR 10527 A CR10527 A CR 10527A
Authority
CR
Costa Rica
Prior art keywords
inibidors
imidazol
potassium channel
compounds
present
Prior art date
Application number
CR10527A
Other languages
English (en)
Inventor
John Michael Janusz
Stephen Joseph Hodson
Gregory Kent Bosch
Ronald Eugene White
Benjamin E Blass
Christopher M Jackson
Neil T Fairweather
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR10527A publication Critical patent/CR10527A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Las 1-N-amino-2-imidazolidinonas de la presente invencion son una nueve clase de compuestos. Se ha encontrado que los compuestos de esta clase inhiben la funcion de los canales de potasio kv1.5. Los compuestos de ejemplo de la presente invencion tienen la formula (I).
CR10527A 2006-06-20 2008-12-18 Inibidores del canal de potasio de imidazol kv1.5 CR10527A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81509106P 2006-06-20 2006-06-20

Publications (1)

Publication Number Publication Date
CR10527A true CR10527A (es) 2009-02-19

Family

ID=38582320

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10527A CR10527A (es) 2006-06-20 2008-12-18 Inibidores del canal de potasio de imidazol kv1.5

Country Status (20)

Country Link
US (2) US7504517B2 (es)
EP (1) EP2035392A1 (es)
JP (1) JP2009541343A (es)
KR (1) KR20090021223A (es)
CN (1) CN101573341A (es)
AR (1) AR061523A1 (es)
AU (1) AU2007260985A1 (es)
BR (1) BRPI0713320A2 (es)
CA (1) CA2655574A1 (es)
CL (1) CL2007001794A1 (es)
CO (1) CO6150173A2 (es)
CR (1) CR10527A (es)
EC (1) ECSP088994A (es)
MX (1) MX2008016399A (es)
NO (1) NO20085252L (es)
PE (1) PE20080942A1 (es)
RU (1) RU2008150465A (es)
TW (1) TW200815363A (es)
WO (1) WO2007149874A1 (es)
ZA (1) ZA200810763B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2655574A1 (en) * 2006-06-20 2007-12-27 Wyeth Imidazole kv1.5 potassium channel inhibitors
RU2373934C1 (ru) * 2008-03-19 2009-11-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
CN101544580B (zh) * 2009-04-28 2019-03-15 大连凯飞精细化工有限公司 R-alpha-氨基-4-甲氧基苯乙酰胺的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099009A (en) * 1977-04-11 1978-07-04 Morton-Norwick Products, Inc. 1-(4-chlorophenyl)-3-(1-ureido)-2-imidazolidinone
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
DE4332168A1 (de) 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1997027180A1 (en) 1996-01-26 1997-07-31 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
CA2250192A1 (en) 1996-04-03 1997-10-09 Chrisopher J. Dinsmore Inhibitors of farnesyl-protein transferase
US7129359B2 (en) 2002-07-09 2006-10-31 National Health Research Institutes Imidazolidinone compounds
HUP0402486A3 (en) 2001-11-30 2007-05-02 Lilly Co Eli Nitrogen containing heterocyclic compounds as peroxisome proliferator activated receptor agonists, their use and pharmaceutical compositions cointaining them
WO2003057214A1 (en) 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
AU2003302027A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
JP2004262903A (ja) 2003-03-04 2004-09-24 Japan Science & Technology Agency アジリジン類の製造方法
US7259174B2 (en) 2004-05-25 2007-08-21 National Health Research Institutes Imidazolidinone compounds
AR050858A1 (es) * 2004-09-07 2006-11-29 Glaxo Group Ltd Compuesto de heteroaril-nitrilo sustituido, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para la preparacion del mismo
KR100677149B1 (ko) 2004-11-12 2007-02-02 삼성전자주식회사 잉크 조성물
CA2655574A1 (en) * 2006-06-20 2007-12-27 Wyeth Imidazole kv1.5 potassium channel inhibitors

Also Published As

Publication number Publication date
US7504517B2 (en) 2009-03-17
US7803827B2 (en) 2010-09-28
US20070299120A1 (en) 2007-12-27
TW200815363A (en) 2008-04-01
ECSP088994A (es) 2009-01-30
CN101573341A (zh) 2009-11-04
JP2009541343A (ja) 2009-11-26
BRPI0713320A2 (pt) 2012-02-07
ZA200810763B (en) 2009-09-30
CA2655574A1 (en) 2007-12-27
AU2007260985A1 (en) 2007-12-27
CL2007001794A1 (es) 2008-01-18
WO2007149874A8 (en) 2008-03-20
CO6150173A2 (es) 2010-04-20
US20090069342A1 (en) 2009-03-12
NO20085252L (no) 2009-01-13
MX2008016399A (es) 2009-02-03
KR20090021223A (ko) 2009-02-27
WO2007149874A1 (en) 2007-12-27
RU2008150465A (ru) 2010-07-27
EP2035392A1 (en) 2009-03-18
PE20080942A1 (es) 2008-09-03
AR061523A1 (es) 2008-09-03

Similar Documents

Publication Publication Date Title
UY28290A1 (es) Compuestos farmacéuticos novedosos
CR11355A (es) Derivados de quinazolinona 6-, 7-, u 8-sustituidos y composiciones que los comprenden
CR9898A (es) Derivados de prolinamida como moduladores del canal de sodio
ECSP12011625A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
PA8796901A1 (es) Inhibidores de la interaccion entre mdm2 y p53
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
ECSP034492A (es) Derivados de hidroxamato utiles como inhibidores de desacetilasa
ECSP10010013A (es) Nuevos fungicidas
HN2009001282A (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal
PA8625201A1 (es) Composiciones de peróxido estabilizadas
PA8667201A1 (es) Nuevos compuestos farmaceuticos
EP4110478C0 (en) DISINFECTANT COMPOSITIONS
JP1780005S (ja) モニター
MX348278B (es) Composiciones dentifricas blanqueadoras no acuosas de tubo unico, metodos de uso y fabricacion de las mismas.
UY30451A1 (es) 18-metil-19-nor-androst-4-en-17,17-espiroéteres (18-metil-19-nor-20-espirox-4-en-3-onas),ase como preparaciones farmacéuticas que lo contienen.
EP4121059A4 (en) NLRP3 MODULATORS
CL2021002108A1 (es) Desinfectante endoscopico mejorado
JP1749764S (ja) プランター
GT200500357A (es) Indazoles substituidos, composicones que los comprenden, procedimiento de su preparacion y utilizacion
DK1608344T3 (da) Orale cladribin-formuleringer
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
EP4384507A4 (en) Deuterated compounds
IL309805A (en) Caspase-2 inhibitor compounds
EP4284362A4 (en) Formulations
NO20063293L (no) Farmasoytiske forbindelser

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)